MedCity News September 16, 2024
Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.
Atopic dermatitis is treatable with many drugs currently on the market, but many patients find these therapies lacking. The FDA has approved an Eli Lilly drug that offers a new biologic treatment option with a dosing schedule that’s less burdensome for patients.
The regulatory decision announced late Friday covers the treatment of adults and children age 12 and older with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription drugs. The Lilly drug, lebrikizumab, will be marketed as Ebglyss, which is the same brand name for the...
Today's Sponsors
Today's Sponsor